Pharmascience
| Primary URL | Location | Industry | www[.]pharmascience[.]com |
Country
Canada
|
Pharmaceuticals
|
|---|
Profile
Pharmascience is a Montreal-based generic pharmaceutical manufacturer. The company focuses on the development and production of generic drug products across various therapeutic categories. Its core activity lies in providing affordable medication alternatives to branded pharmaceuticals.
The available source material does not disclose specific figures regarding the company's size, workforce, or geographic reach. Consequently, details such as annual revenue, number of employees, or the extent of its market presence are not stated in the provided information.
As a generic manufacturer, Pharmascience operates under regulatory frameworks that govern the approval and quality standards of off‑patent medicines. Its specialization in generic formulations positions it within a sector that emphasizes cost‑effective healthcare solutions. The firm’s location in Montreal situates it within a Canadian pharmaceutical hub known for research and manufacturing activity. These attributes highlight its role in supplying therapeutically equivalent products to patients and health systems.
Information about the company's ownership structure, parent entities, or subsidiary relationships is not included in the source material. Therefore, any description of its corporate affiliations would be speculative and is omitted.
In June 2024, Pharmascience experienced a cybersecurity breach characterized by unauthorized access to its systems, prompting the engagement of external experts to secure its IT infrastructure. The company reported that there were no production disruptions and that systems were restored, allowing safe operations to resume, while withholding specifics on the attack’s duration, scope, any ransom demands, or potential data exfiltration. This incident underscores the broader vulnerability of the pharmaceutical sector, where just‑in‑time production models could amplify supply shortages if manufacturing is disrupted. It aligns with industry trends of escalating cyberattacks targeting pharmaceutical firms, driven by their financial capacity and the sensitivity of the data they hold, although direct operational or supply impacts from this event remain unconfirmed.